CRBU Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Caribou Biosciences Inc (CRBU) is not a strong buy at the moment for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock's recent price decline, lack of significant positive catalysts, and weak financial performance do not currently align with a strong long-term investment opportunity. Holding off for now is recommended.
The MACD is slightly positive but contracting, RSI is neutral at 45.057, and moving averages are converging, indicating no strong trend. The stock is trading below the pivot level of 1.554, with support at 1.416 and resistance at 1.691. Overall, the technical indicators suggest a neutral to slightly bearish trend.
Hedge funds have significantly increased their buying activity, up 1731.04% in the last quarter. Analysts maintain a Buy rating with a long-term price target of $13, citing potential in CAR-T therapies and a promising pipeline.
The stock price has declined by 4.40% in the regular market and 0.63% in pre-market trading. Financial performance is weak, with net income and EPS declining significantly in the latest quarter. No recent news or congress trading data to act as a catalyst.
In Q3 2025, revenue grew by 8.60% YoY to $2.198M, but net income dropped by 20.57% YoY to -$27.548M, and EPS fell by 21.05% YoY to -0.3. Gross margin remained flat at 100%. Overall, the company is not profitable and is experiencing declining earnings.
Analysts are optimistic about the long-term potential of CRBU, with a Buy rating and price targets ranging from $6 to $13. However, the timeline for realizing this potential is long, with peak sales projections for key products not expected until 2040.
